Looks like an exciting 2013 from the J.P. Morgan Healthcare Conference

>
29 of 40
<

Richard Pops, chairman and CEO of Alkermes

Richard Pops was fired up during our lunch with him during the J.P. Morgan Healthcare Conference. Alkermes ($ALKS) has potential blockbuster psychiatric drugs in its pipeline, led by the Ireland-based company's long-acting version of Abilify, ALKS-9070, in late-stage development. Imagine an Alkermes where the handsome income stream from Johnson & Johnson's ($JNJ) Risperdal Consta seems quaint? Referencing his bigger Boston-area neighbors, Pops said: "We're going to build a Biogen or a Vertex."